At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 65 enrolled
Drug / intervention
Escitalopramdrug
Likely dose
Escitalopram 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacologic Influence of Escitalopram on the Reduction of Fear Acquisition and Triggered Renewal During Fear Conditioning: a Model for the Prevention and Persistence of Learned Fear and Anxiety in Response to Trauma and Stress
In Brief
A Phase 4 clinical trial evaluating Escitalopram for Fear Conditioning. Completed, enrolled 65 participants.
Detailed Summary
The purpose of the study is to learn how differences in learning under mildly-stressful circumstances may be changed by taking an antidepressant medication. This medication is called Lexapro (Escitalopram). The investigators will also examine the impact of any anxiety, depression, and stress related symptoms on learning processes. The investigators will also look at the response of these symptoms to Lexapro.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFear Conditioning
Countries--
CollaboratorsForest Laboratories
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
Primary CompletionJun 2011
First PostedJul 2011
TodayJul 2026
First PostedJul 20, 2011
Enrollment StartOct 1, 2008
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 15.0 years ago
Interventions
Escitalopramdrug
Escitalopram 10mg/day or matched pill placebo